Skip to main content

NCT01550744 - A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


CSR Summary

Not Yet Available


Data Specification

Not Available


Annotated CRF

Not Available

Product Info

Generic Name
Ustekinumab
Product Name
STELARA®
Therapeutic Area
Skin and Connective Tissue Diseases
Enrollment
478
% Female
37.6%
% White
N/A
Product Class
Antipsoriatics
Sponsor Protocol Number
CNTO1275PSO3009
Data Partner
Johnson & Johnson
Condition Studied
Psoriasis
Mean/Median Age (Years)
45.1

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

APPROVED DATA REQUESTS ASSOCIATED WITH THIS TRIAL

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.